Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine

• Published in: Vaccines (Basel) Vol. 9; no. 9; p. 946
• Main Authors: Lebeau, Grégorie, Lagrave, Alisé, Ogire, Eva, Grondin, Lauriane, Seriacaroupin, Soundary, Moutoussamy, Cédric, Mavingui, Patrick, Hoarau, Jean-Jacques, Roche, Marjolaine, Krejbich-Trotot, Pascale, Desprès, Philippe, Viranaicken, Wildriss
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 25.08.2021; MDPI
• Subjects: Antibodies; Antigens; arbovirus; Cytokines; dengue; Dengue fever; Dengue hemorrhagic fever; Disease; Fever; Genomes; Hemorrhage; Immunopathogenesis; Infections; Life Sciences; Microbiology and Parasitology; Mosquitoes; NS1; Pathogenesis; Proteins; Public health; Review; Serotypes; Toxins; Vaccine development; Vaccines; Vector-borne diseases; Viral diseases; viral hemorrhagic fever; viral immunopathogenesis; viral toxin; Virology; West Nile virus; viral toxin; viral hemorrhagic fever; dengue vaccine strategies; viral immunopathogenesis; dengue; NS1; arbovirus
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines9090946

The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of four genetically related but antigenically distinct serotypes DENV-1–DENV-4. The growing burden of the four DENV serotypes has intensified both basic and applied research to better understand dengue physiopathology. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Here, we provide an overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. We discuss the potential use of sNS1 in future vaccine development and its potential to improve dengue vaccine efficiency, particularly against severe dengue illness.